$0.83
0.03[3.75%]
Last update: 9:24AM Get Real Time Here
Achilles Therapeutics
(NASDAQ:ACHL)Achilles Therapeutics Stock (NASDAQ:ACHL), Analyst Ratings, Price Targets, Predictions
Achilles Therapeutics PLC has a consensus price target of $10.42, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Chardan Capital, and B of A Securities on April 5, 2024, April 5, 2024, and December 14, 2023. With an average price target of $2.83 between Piper Sandler, Chardan Capital, and B of A Securities, there's an implied 241.37% upside for Achilles Therapeutics PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Chardan Capital
B of A Securities
JP Morgan
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Achilles Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 140.96% | Piper Sandler | Joseph Catanzaro | $8 → $2 | Downgrade | Overweight → Neutral | Get Alert |
| 04/05/2024 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 622.89% | Chardan Capital | Geulah Livshits | $11 → $6 | Maintains | Buy | Get Alert |
| 12/14/2023 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | -39.76% | B of A Securities | Tazeen Ahmad | $7 → $0.5 | Downgrade | Buy → Underperform | Get Alert |
| 08/07/2023 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 1225.3% | Chardan Capital | Geulah Livshits | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 1225.3% | Chardan Capital | Geulah Livshits | $12 → $11 | Maintains | Buy | Get Alert |
| 12/07/2022 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 1948.19% | Chardan Capital | Geulah Livshits | $20 → $17 | Maintains | Buy | Get Alert |
| 12/07/2022 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 863.86% | Piper Sandler | Joseph Catanzaro | $10 → $8 | Maintains | Overweight | Get Alert |
| 04/26/2021 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 1225.3% | JP Morgan | Eric Joseph | — | Initiates | → Underweight | Get Alert |
| 04/26/2021 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 2309.64% | B of A Securities | — | — | Initiates | → Buy | Get Alert |
| 04/26/2021 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 3153.01% | Chardan Capital | Geulah Livshits | — | Initiates | → Buy | Get Alert |
| 04/26/2021 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 2912.05% | Piper Sandler | Joseph Catanzaro | — | Initiates | → Overweight | Get Alert |
| 04/26/2021 | ACHL | Buy Now | Achilles Therapeutics | $0.83 | 2671.08% | Oppenheimer | Mark Breidenbach | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Achilles Therapeutics (ACHL)?
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Piper Sandler on April 5, 2024. The analyst firm set a price target for $2.00 expecting ACHL to rise to within 12 months (a possible 140.96% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Piper Sandler, and Achilles Therapeutics downgraded their neutral rating.
When was the last upgrade for Achilles Therapeutics (ACHL)?
There is no last upgrade for Achilles Therapeutics.
When was the last downgrade for Achilles Therapeutics (ACHL)?
The last downgrade for Achilles Therapeutics PLC happened on April 5, 2024 when Piper Sandler changed their price target from $8 to $2 for Achilles Therapeutics PLC.
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a downgraded with a price target of $8.00 to $2.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.